Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin-based regimen versus tetracycline-bismuth quadruple therapy for Helicobacter pylori eradication
IRCT20191010045053N1Phase 4Completed
- Sponsor
- University of Zakho
- Start
- Dec 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of levofloxacin, tetracycline, bismuth subcitrate, metronidazole, amoxicillin and 1 more in Helicobacter pylori infection (2 arms), sponsored by University of Zakho. Primary endpoint: Helicobacter pylori eradication. Started Dec 2019; status: completed.
02
Drugs
levofloxacintetracyclinebismuth subcitratemetronidazoleamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20191010045053N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191010045053N1.